Novo Nordisk says Semaglutide approved for long-term weight management in China

By Andrew Silver

SHANGHAI (Reuters) – Novo Nordisk’s drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday.

The Danish drugmaker did not immediately respond to a Reuters request for comment.

In March, it said the company would initially focus on patients paying out-of-pocket for the injectable drug, which has seen strong demand in other markets.

Novo’s patent on Semaglutide in China expires in 2026.

(Reporting by Andrew Silver; Editing by Jacqueline Wong and Kim Coghill)